Xianling Lianxia formula improves the efficacy of trastuzumab by enhancing NK cell-mediated ADCC in HER2-positive BCOA
Xianling Lianxia formula improves the efficacy of trastuzumab by enhancing NK cell-mediated ADCC in HER2-positive BC
Feifei Li;Youyang Shi;Mei Ma;Xiaojuan Yang;Xiaosong Chen;Ying Xie;Sheng Liu
Department of Breast Surgery,Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai,200030,China||Institute of Chinese Traditional Surgery,Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai,200030,ChinaDepartment of Breast Surgery,Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai,200030,ChinaInstitute of Toxicology,School of Public Health,Lanzhou University,Lanzhou,730000,ChinaDepartment of Breast Surgery,Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai,200030,ChinaDepartment of General Surgery,Comprehensive Breast Health Center,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai,200001,ChinaInstitute of Chinese Traditional Surgery,Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai,200030,ChinaDepartment of Breast Surgery,Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai,200030,China||Institute of Chinese Traditional Surgery,Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai,200030,China
HER2-positive breast cancerTraditional chinese medicineTrastuzumabNK cellADCC effect
HER2-positive breast cancerTraditional chinese medicineTrastuzumabNK cellADCC effect
《药物分析学报（英文）》 2024 (10)
1450-1467,18
This work was supported by the National Natural Science Foundation of China(Grant No.:81774308),the Multi-center Clin-ical Research Project for Major Diseases of Shanghai Shenkang Hospital Development Center,China(Grant No.:SHDC2020CR1050B),and the High-level University Building Inno-vation Team,China(Grant No.:601521D).
评论